Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review
| Autor: | Julia A Critchley, Yenal Dundar |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Drug
medicine.medical_specialty business.industry Low molecular weight iron media_common.quotation_subject Intravenous iron Hematology Pharmacology Iron sucrose medicine.disease Surgery Medical–Surgical Nursing chemistry.chemical_compound Anesthesiology and Pain Medicine Dextran Iron-deficiency anemia chemistry Immunology and Allergy Iron dextran Medicine business Adverse effect media_common medicine.drug |
| Zdroj: | Transfusion Alternatives in Transfusion Medicine. 9:8-36 |
| ISSN: | 1778-428X 1295-9022 |
| DOI: | 10.1111/j.1778-428x.2007.00042.x |
| Popis: | SUMMARY Intravenous iron administration is an effective method of treating iron deficiency anemia, but there have been concerns about adverse side effects, particularly serious events such as anaphylactic reaction. Several different forms of intravenous iron are available, but few studies have attempted to compare the frequency of adverse events. We carried out a systematic review to assess the frequency of adverse drug events (ADEs) associated with (i) low-molecular-weight intravenous iron dextran and (ii) iron sucrose. We searched several electronic databases; two reviewers screened all studies identified and extracted data. We included 60 studies, but few directly compared adverse events associated with two or more forms of iron, and most were not specifically designed to evaluate adverse events. In general, with the exception of high-molecular-weight iron dextran (HMWID), serious or life-threatening adverse events appeared rare. Several studies showed lower risks of ADEs on low-molecular-weight iron dextran (LMWID) compared with HMWID, and one large review found a reduced risk on LMWID compared with iron gluconate. Two studies showed little difference between iron sucrose and iron gluconate, and two further studies had similar rates of adverse drug events between iron sucrose and LMWID; however, the sample size for most of these studies was too small to draw firm conclusions. Adequately powered direct comparisons of different forms of intravenous iron are required to assess the safety profiles. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|